Component
Hypophosphatemia after intravenous iron
Hypophosphatemia after intravenous iron. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Phosphate below 2.0 mg/dL occurred in 50.8% with ferric carboxymaltose versus 0.9% with ferumoxytol; low phosphate persisted at five weeks in 29.1% versus none.
Experimental context and source evidence
- availability_state
- nutrient_deficiency Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/iron-research/30518682.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257", "start_char": 0, "end_char": 2371, "text_sha256": "489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257"}
- experimental_model
- Double-blind randomized comparison with physiological substudy
- exposure
- One treatment course of ferric carboxymaltose versus ferumoxytol; five-week follow-up
- limitations
- Formulation-specific pharmacological effect, not dietary iron or all intravenous iron. Trial funded by ferumoxytol manufacturer; mineral associations support but do not individually prove every causal arrow.
- nutrient_topic
- Iron research collection; topical membership is not evidence of a direct dietary effect. · Iron
- organism
- 1997 adults with iron-deficiency anemia; 185 in substudy
- plain_language
- The phosphate risk depended strongly on the iron formulation.
- primary_references
- [iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486
- tissue_or_cell_type
- Blood and renal phosphate handling
- trigger_kind
- nutrient_deficiency Imported condition classification; unverified.
Iron: absorption, trafficking, iron-dependent enzymes and nutrient interactions (2026-09-17) · lines 940–951
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind randomized comparison with physiological substudy · source_derived_draft · unverified_draft
### iron-fcm-phosphate-frequency Phosphate below 2.0 mg/dL occurred in 50.8% with ferric carboxymaltose versus 0.9% with ferumoxytol; low phosphate persisted at five weeks in 29.1% versus none. Condition category: nutrient_deficiency nutrient_topic: Iron research collection; topical membership is not evidence of a direct dietary effect. plain_language: The phosphate risk depended strongly on the iron formulation. organism: 1997 adults with iron-deficiency anemia; 185 in substudy tissue_or_cell_type: Blood and renal phosphate handling experimental_model: Double-blind randomized comparison with physiological substudy limitations: Formulation-specific pharmacological effect, not dietary iron or all intravenous iron. Trial funded by ferumoxytol manufacturer; mineral associations support but do not individually prove every causal arrow. exposure: One treatment course of ferric carboxymaltose versus ferumoxytol; five-week follow-up evidence_span: {"source_cache": "artifacts/iron-research/30518682.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257", "start_char": 0, "end_char": 2371, "text_sha256": "489945718bb05c0630fd563dc5a6da0874e80685717ab06ceedfefc38d172257"} [iron-p30518682] Randomized trial of intravenous iron-induced hypophosphatemia. (2018). https://pubmed.ncbi.nlm.nih.gov/30518682/ DOI: 10.1172/jci.insight.124486
Complete structured claim and evidenceHypophosphatemia occurred in 7.9% versus 75.0% in trial A and 8.1% versus 73.7% in trial B with derisomaltose versus carboxymaltose.
Experimental context and source evidence
- availability_state
- nutrient_deficiency Imported condition classification; unverified.
- evidence_span
- {"source_cache": "artifacts/iron-research/32016310.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a", "start_char": 0, "end_char": 2731, "text_sha256": "883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a"}
- experimental_model
- Two open-label randomized trials
- exposure
- Ferric derisomaltose 1000 mg once versus ferric carboxymaltose 750 mg twice; 35 days
- limitations
- Formulation and total regimen differed; no fracture endpoint or identical risk in all populations is inferred.
- nutrient_topic
- Iron research collection; topical membership is not evidence of a direct dietary effect. · Iron
- organism
- 245 adults, predominantly women, without reduced kidney function
- plain_language
- A second pair of trials also found that iron formulations differed in their phosphate effects.
- primary_references
- [iron-p32016310] Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (2020). https://pubmed.ncbi.nlm.nih.gov/32016310/ DOI: 10.1001/jama.2019.22450
- tissue_or_cell_type
- Serum phosphate
- trigger_kind
- nutrient_deficiency Imported condition classification; unverified.
Iron: absorption, trafficking, iron-dependent enzymes and nutrient interactions (2026-09-17) · lines 992–1003
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two open-label randomized trials · source_derived_draft · unverified_draft
### iron-fdi-fcm-comparison Hypophosphatemia occurred in 7.9% versus 75.0% in trial A and 8.1% versus 73.7% in trial B with derisomaltose versus carboxymaltose. Condition category: nutrient_deficiency nutrient_topic: Iron research collection; topical membership is not evidence of a direct dietary effect. plain_language: A second pair of trials also found that iron formulations differed in their phosphate effects. organism: 245 adults, predominantly women, without reduced kidney function tissue_or_cell_type: Serum phosphate experimental_model: Two open-label randomized trials limitations: Formulation and total regimen differed; no fracture endpoint or identical risk in all populations is inferred. exposure: Ferric derisomaltose 1000 mg once versus ferric carboxymaltose 750 mg twice; 35 days evidence_span: {"source_cache": "artifacts/iron-research/32016310.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a", "start_char": 0, "end_char": 2731, "text_sha256": "883aac76c40012cb98ac88924e33b33f4985d356302929b8b26931c1869e2f0a"} [iron-p32016310] Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (2020). https://pubmed.ncbi.nlm.nih.gov/32016310/ DOI: 10.1001/jama.2019.22450
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.